March 19, 2021 5:33pm

Beats yesterday’s downdraft

Pre-open indication results: 5 HITs and 1 MISS

Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion!

The week in review ...  differences are significant 

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

The Dow closed DOWN -234.33 points (-0.71%); the S&P closed DOWN -2.36 points (-0.06%) while the Nasdaq closed UP +99.07 points (+0.76%)

 

Henry’omics:

The Dow and S&P fell on Friday supposedly after the Fed’s decision to not extend a pandemic-era capital break for banks stoked a rise in bond yields and a sell-off in financial stocks.

The cell and gene therapy sector flipped higher after yesterday’s drubbing as the Nasdaq moved higher

For the week, the major averages post a loss with the Dow down -0.05%, the S&P 500 off by -0.8% and the Nasdaq -0.8%.

 

RegMed Investors’ (RMi) pre-open: “welcome to Friday and a bounce back after 2 positive (Monday, Wednesday) and 2 negative (Tuesday, Thursday) closes; the IBB being up three (3) sessions and the XBI up two (2) sessions with the CBOE Volatility Index (VVIX) spending three (3) sessions down” … https://www.regmedinvestors.com/articles/11823

 

Pre-open indication results:  5 HITs < Falling Knife: Solid Biosciences (SLDB -$0.23); BUY: Applied Genetic Technologies (AGTC +$0.29), Pluristem (PSTI +$0.10), CRISPR Therapeutics (CRSP +$6.04), Editas Medicine (EDIT +$1.75) and 1 MISS < Biostage (BSTG +$0.13 with 605 shares)>

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Friday opened positive at 21/13, 1 flat and 1 acquired, stayed positive at the mid-day to 31/3 and 1 acquired, closing positive at 32/2 and 1 acquired;
  • Thursday opened negative at 5/28, 1 flat and 1 acquired, stayed negative at the mid-day to 9/25 and 1 acquired, closing negative at 4/29, 1 flat and 1 acquired;
  • Wednesday opened negative at 5/28, 1 flat and 1 acquired, stayed negative at the mid-day to 10/24, 3 flat and 1 acquired, closing positive at 25/8, 1 flat and 1 acquired;
  • Tuesday opened negative at 11/22, 1 flat and 1 acquired, stayed negative at the mid-day to 11231 and 1 acquired, closing negative at 4/30 and 1 acquired;
  • Monday opened positive at 24/9, 1 flat and 1 acquired, stayed positive at the mid-day to 23/11 and 1 acquired, closing positive at 25/9 and 1 acquired;

 

There are clear winners and losers

Jumping with share pricing momentum:

  • ReNeuron (RENE.L), Vericel (VCEL), CRISPR Therapeutics (CRSP), Ultragenyx (RARE) Fate Therapeutics (FATE) to name 5 of the 32 inclining of the 35 covered

Hammered in today’s market:

  • Precigen (PGEN), Solid Biosciences (SLDB) to name 2 of the 2 declining of the 35 covered

 

Key metrics:

  • Sector volume had definitely INCREASED with 22 of the 32-upside having higher than the 3-month average volume with the volume of 2 of 2-downside having higher than the 3-month average volume;
  • Friday’s percentage (%) of the 32-upside were +0.43% (MESO) to +15.21% (MDXG) while the 2-downside ranges from -3.08% (PGEN) to -3.80% (SLDB);

 

Friday’s (10 of 32) incline

  • ReNeuron (RENE.L +$15.00 after Thursday’s +$0.50, Wednesday’s -$3.00, Tuesday’s +$9.00 and Monday’s +$1.00);
  • Vericel (VCEL+$6.41 after Thursday’s +$6.29, Wednesday’s +$1.36 and Tuesday’s -$1.95);
  • CRISPR Therapeutics (CRSP +$6.04 after Thursday’s -$7.53 and Wednesday’s +$0.53);
  • Ultragenyx (RARE +$4.74 after Thursday’s -$8.89 and Wednesday’s -$0.38);
  • Fate Therapeutics (FATE +4.32 after Thursday’s -$5.80, Wednesday’s +$2.04, Tuesday’s -$3.04 and Monday’s -$1.22);
  • Alnylam Pharmaceuticals (ALNY +$4.12 after Thursday’s -$5.11, Wednesday’s +$1.37, Tuesday’s -$2.34 and Monday’s +$3.92);
  • Intellia Therapeutics (NTLA +$3.62 after Thursday’s -$4.94, Wednesday’s +$1.47, Tuesday’s -$2.51 and Monday’s +$2.54);
  • Editas Medicine (EDIT +$1.75 after Thursday’s -$3.32, Wednesday’s +$0.90, Tuesday’s -$2.30 and Monday’s +$1.69);
  • Sage Therapeutics (SAGE +$1.62 after Thursday’s -$3.91, Wednesday’s +$2.50 and Tuesday’s -$2.84);
  • Cellectis SA (+$1.62);

Friday’s (2 of 2) decliners:

  • Precigen (PGEN -$0.26);
  • Solid Biosciences (SLDB -$0.23 after public offering announcement);

Closing: 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19 infections:

  • As more Americans seek vaccination, more states are allowing larger indoor gatherings and announcing reopening guidelines for businesses, like stadiums and health clubs.

Infection cases <Million>: never to forget …

  • Friday 29.67 M cases,
  • Friday’s death rate totaled 539,801 <Johns Hopkins University>

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed up +1.70% and XBI closed up +3.26%
  • Thursday, the IBB closed down -3.10% and XBI closed down -4.77%
  • Wednesday, the IBB closed up +0.70% and XBI closed up +1.12%
  • Tuesday, the IBB closed up +0.02% and XBI closed down -1.57%
  • Monday, the IBB closed up +1.49% and XBI closed up +2.17%

 

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was down -0.63. points or -2.92% at 20.95
  • Thursday was up +2.35. points or +12.22% at 21.58
  • Wednesday was down -0.56 points or -2.83% at 19.23
  • Tuesday was down -0.24 points or -1.20% at 19.79
  • Monday was down -0.66 points or -3.19% at 20.03

 

Upside volume: 

  • Friday: 22 out of the 32-upside had higher than the 3-month average volume;
  • Thursday: 2 out of the 4-upside had higher than the 3-month average volume;
  • Wednesday: 2 out of the 25-upside had higher than the 3-month average volume;
  • Tuesday: 1 out of the 4-upside had higher than the 3-month average volume;
  • Monday: 0 out of the 25-upside had higher than the 3-month average volume;

 

Downside volume: 

  • Friday: 2 out of the 2-downside had higher than the 3-month average volume;
  • Thursday: 3 out of the 29-downside had higher than the 3-month average volume;
  • Wednesday: 1 out of the 8-downside had higher than the 3-month average volume;
  • Tuesday: 3 out of the 30-downside had higher than the 3-month average volume;
  • Monday: 0 out of the 9-downside had higher than the 3-month average volume;

 

Percentage (%) movement/range statistics: % and pricing drop

  • Friday’s percentage (%) of the 32-upside were +0.43% (MESO) to +15.21% (MDXG) while the 2-downside ranges from -3.08% (PGEN) to -3.80% (SLDB);
  • Thursday’s percentage (%) of the 4-upside were +0.46% (RENE.L) to +13.45% (VCEL) while the 29-downside ranges from -0.38% (AXGN) to -9.20% (SLDB);
  • Wednesday’s percentage (%) of the 25-upside were +0.11% (GBT) to +5.31% (VSTM) while the 8-downside ranges from -0.29% (RARE) to -4.29% (BLUE);
  • Tuesday’s percentage (%) of the 4-upside were +0.92% (CLLS) to +8.82% (RENE.L) while the 30-downside ranges from -0.01% (RARE) to -32.39% (SLDB);
  • Monday’s percentage (%) of the 25-upside were +0.55% (MDXG) to +12.02% (AGTC) while the 9-downside ranges from -0.11% (SLDB) to -3.23% (CLBS);

 

March, the 3rd month of Q1/21:

Friday closed positive with 32 advancers, 2 decliners and 1 acquired

Thursday closed negative with 4 advancers, 29 decliners, 1 flat and 1 acquired

Wednesday closed positive with 25 advancers, 8 decliners, 1 flat and 1 acquired

Tuesday closed negative with 4 advancers, 30 decliners and 1 acquired

Monday (3/15) closed positive with 25 advancers, 9 decliners and 1 acquired

Friday closed negative with 12 advancers, 22 decliners and 1 acquired

Thursday closed positive with 28 advancers, 6 decliners and 1 acquired

Wednesday closed neutral with 15 advancers, 15 decliners, 4 flat and 1 acquired

Tuesday closed positive with 30 advancers, 4 decliners and 1 acquired

Monday (3/8) closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

Friday closed positive with 18 advancers, 14 decliners, 2 flats and 1 acquired

Thursday closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

Wednesday closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

Tuesday closed negative with 8 advancers, 26 decliners and 1 acquired

Monday (3/1) closed positive with 27 advancers, 6 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: the sector is back with momentum to the upside after the slide of Thursday, Wednesday’s uplift following Tuesday’s slide and Monday’s upside following last Friday’s slippage.

This roller-coaster ride cost us money but, it still shows sustainability is the real issue in “this” market!

NOT for me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run as volatility rules!

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice has been … trim and skim … if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.